ImmuCell Corporation (ICCC) Stock

Understand ImmuCell Corporation: how it makes money

ImmuCell makes biological products (scours preventives, antibody treatments, and mastitis tests) for dairy and beef cattle, selling them to producers and veterinarians in the US and abroad. Revenue is modest and scales with cattle birth volumes, so the growth story is about lifting penetration into a large untreated-calf population rather than expanding the customer base.

Every dollar of revenue is tied to a specific animal treated: the company monetizes per-calf scours prevention and mastitis testing, so growth is a function of cattle births times penetration rate, not of price increases on a fixed account base.

Business quality (Unprofitable): Solid 27% operating margin in a narrow niche, but the company has yet to clear the line to net profitability, and the addressable market is small enough that a single季的 misstep or a distributor timing swing moves the whole picture.

Bull case

• Share gained in core market: Management cited a rise in treated-calf market share from 10% to 15% over eight years on the Q4 FY25 call, a structural shift in how producers approach scours prevention that compounds each year.
• Supply ceiling about to lift: Capacity expansion aimed at removing the production constraint that has capped how many calves can be treated, which should let revenue grow in line with demand rather than being throttled by the plant.
• Margin headroom from scale: Gross margin sits at 34% and management attributed recent expansion to higher volumes, efficiencies, and pricing, suggesting further margin leverage as output scales toward the expanded capacity.

Bear case

• International sales cliff: International product sales declined more than half in Q4 FY25, leaving a meaningful slice of revenue hostage to distributor ordering timing rather than underlying farm demand, and a repeat of that gap would drag the whole P&L.
• Still at net loss: Despite a 27% operating margin in the latest quarter, the company remained loss-making on a net-income basis in fiscal 2025, meaning the bottom line has not yet caught up to the operating story and shareholders have no dividend or buyback cushion.
• Impairment flags strategy risk: A $2.7 million non-cash impairment charge followed a shift in the company's retained strategy, a reminder that not every growth option is working out and that capital deployed into underperforming lines can take years to recover.

ImmuCell Corporation earnings call transcripts

• ICCC Q4 FY25 earnings call transcript (reported 2026-03-04) · analysis
• ICCC Q2 FY25 earnings call transcript (reported 2025-08-14) · analysis

All ICCC earnings calls

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

• Alpha Teknova, Inc. (TKNO)
• Biomerica, Inc. (BMRA)
• Insight Molecular Diagnostics Inc. (IMDX)
• American Shared Hospital Services (AMS)
• OmniAb, Inc. (OABI)
• VolitionRx Limited (VNRX)
• Q/C Technologies, Inc. (QCLS)
• Exagen Inc. (XGN)